Is it time to let AI (artificial intelligence) take-over clinical decision-making? #MSBlog #MSResearch #ClinicSpeak
"Can we manage MS using a simple algorithm or flowchart? The review paper below suggests this is possible. I have always been reluctant to formulate algorithms; in my opinion there are simply too many personal decisions that need to be considered when choosing a treatment strategy and/or DMT to make a easy to use algorithm possible. May be I am wrong? Do you think there is a need for an app, powered by an algorithm, to help you make a decision regarding DMTs? I suspect if the app was intelligent enough it could perform as well, if not better, than a neurologist who may have certain biases when it comes to prescribing DMTs."
Epub: Ingwersen et al. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics. 2015 Dec 23.
Treatment options in relapsing-remitting multiple sclerosis have increased considerably in recent years; currently, a dozen different preparations of disease-modifying therapies are available and some more are expected to be marketed soon. For the treating neurologist this broad therapeutic repertoire not only greatly improves individualized management of the disease, but also makes choices more complex and difficult. A number of factors must be considered, including disease activity and severity, safety profile, and patient preference. We here discuss the currently existing options and suggest treatment algorithms for managing relapsing-remitting multiple sclerosis.
Labels: App, ClinicSpeak, DMTs, treatment algorithms